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a b s t r a c t
Vpr and Vpx are a group of highly related accessory proteins from primate lentiviruses. Despite the high
degree of amino acid homology within this group, these proteins can be highly divergent in their
functions. In this work, we constructed chimeric and mutant proteins between HIV-1 and SIVagm Vpr in
order to better understand the structure–function relationships. We tested these constructs for their
abilities to induce G2 arrest in human cells and to degrade agmSAMHD1 and Mus81. We found that the
C-terminus of HIV-1 Vpr, when transferred onto SIVagm Vpr, provides the latter with the de novo ability
to induce G2 arrest in human cells. We conﬁrmed that HIV-1 Vpr induces degradation of Mus81
although, surprisingly, degradation is independent and genetically separable from Vpr's ability to induce
G2 arrest.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The HIV-1 genome encodes structural proteins (Gag, Pol and Env),
regulatory proteins (Tat and Rev), and accessory proteins such as Vif,
Vpr, Vpu and Nef. HIV-2, SIVmac and SIVsmm encode Vpr, Vpx, Vif
and Nef as accessory proteins. Vpr and Vpx from HIV-2, SIVmac and
SIVsmm are highly related to each other and are thought to have
arisen through gene duplication (Tristem et al., 1992). SIVagm
encodes Vif, Vpr and Nef. A Vpu homolog is not found in the HIV-
2/SIVmac/SIVsmm or the SIVagm phylogenetic groups.
From the entry step to the time of release from the host cell,
lentiviruses encounter several restriction factors that function to
inhibit viral infection and are considered innate immune effector
mechanisms. TRIM5α, APOBEC3G, sterile alpha motif (SAM) and
HD domain-containing protein 1 (SAMHD1) and tetherin are
examples of host restriction factors. These restriction factors are
typically overcome by the accessory proteins encoded by lenti-
viruses (reviewed in (Strebel, 2013)).
Three of the four accessory proteins in each HIV-1 (Vif, Vpr and
Vpu) and HIV-2 (Vif, Vpr and Vpx) antagonize innate immunity by
a common mechanism, the ubiquitin–proteasome system (UPS).
These proteins modify the speciﬁcity of cullin-RING ubiquitin
ligases (CRUL) such that non-cognate proteins are modiﬁed and
later degraded.
Vpr has been associated with induction of cell cycle arrest in G2
and apoptosis (He et al., 1995; Jowett et al., 1995; Stewart et al.,
1997). Vpr induces these effects via activation of the ATR kinase
(Roshal et al., 2003), a result of manipulation of the ubiquitin
ligase CRUL4DDB1/DCAF1 (Belzile et al., 2007; DeHart et al., 2007;
Hrecka et al., 2007; Le Rouzic et al., 2007; Schrofelbauer et al.,
2007; Wen et al., 2007). Recently, the ubiquitination target for the
Vpr/CRUL4 complex has been identiﬁed (Laguette et al., 2014). Vpr
induces premature activation of the SLX4 complex (SLX4com)
(Laguette et al., 2014). Vpr increases the binding of DCAF1 to the
scaffold protein SLX4 and, together with the polo-like kinase-1
(PLK1), promotes SLX4com remodeling, which results in Mus81
degradation (Laguette et al., 2014). As a consequence of the
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untimely SLX4com activation, replication forks are processed
incorrectly causing cell cycle arrest in G2 (Laguette et al., 2014).
The authors showed that by activating SLX4, Vpr prevents the viral
DNA from stimulating cellular DNA sensors, which would normally
trigger a type-I interferon response (Laguette et al., 2014)
Nuclear magnetic resonance (NMR) studies indicate that HIV-1
Vpr is comprised of three bundled alpha helices connected by
short ﬂexible loops and ﬂanked by ﬂexible amino- and carboxy-
terminal unstructured regions (Morellet et al., 2003). The region
on Vpr that binds to DCAF1 was mapped within the third α-helix,
involving a leucine-rich motif (DeHart et al., 2007; Le Rouzic et al.,
2007). The Vpr Q65R amino acid substitution within this region
disrupts the interaction between Vpr and DCAF1 resulting in
inability to induce G2 arrest (DeHart et al., 2007; Le Rouzic et al.,
2007). The C-terminal unstructured region of Vpr is predicted to
be required for interaction with the target, since the mutant R80A
within that region is capable of interacting with DCAF1 but is
unable to cause G2 arrest (DeHart et al., 2007). Furthermore, Vpr
R80A acts as a dominant-negative protein because it binds to
DCAF1 and blocks the Vpr-binding site (DeHart et al., 2007;
Le Rouzic et al., 2007).
Vpx is encapsidated in HIV-2 and SIVmac virions and antag-
onizes SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011).
SAMHD1 interferes with the ability of the virus to efﬁciently
synthesize viral cDNA during reverse transcription because it
reduces the available cellular pools of dNTPs (Goldstone et al.,
2011). Consequently, SAMHD1 diminishes the capacity of the virus
to infect macrophages, dendritic cells and quiescent T-cells
wherein dNTP levels are normally very low (Hrecka et al., 2011;
Laguette et al., 2011). Vpx triggers degradation of SAMHD1 by
associating with DCAF1 and recruiting SAMHD1 to the CRUL4DDB1/
DCAF1 E3 ligase. SAMHD1 is subsequently ubiquitinated and
degraded by the proteasome. Inhibition of the interaction between
Vpx and DCAF1 by the mutant Vpx (Q76A) results in failure to
degrade SAMHD1. HIV-1 Vpr and SIVmac Vpx appear to bind to
similar or overlapping regions on DCAF1, although the amino acid
residues in DCAF1 involved in interaction with either accessory
protein are not identical (Cassiday et al., 2014).
African green monkeys (AGM) are endemically infected with
several strains of simian immunodeﬁciency viruses collectively
known as SIVagm (Jin et al., 1994). This group of primate
lentiviruses encode three accessory genes: Vpr, Vif and Nef.
SIVagm Vpr is bifunctional because it can induce G2 arrest and
also antagonize SAMHD1. Unlike HIV-1 Vpr, SIVagm Vpr is highly
species-speciﬁc, as it induces G2 arrest in AGM cells but not in
human ones (Fletcher et al., 1996; Planelles et al., 1996), and is able
to degrade agmSAMHD1 but not human SAMHD1 (hSAMHD1)
(Lim et al., 2012).
In order to understand the structure–function relationships for
HIV-1 Vpr and SIVagm Vpr we constructed chimeric proteins by
exchanging homologous domains of HIV-1NL4-3 Vpr and SIVagm.
gri Vpr. We then investigated the ability of the different chimeras
to cause cell cycle arrest in G2 and to induce degradation of
SAMHD1 and Mus81. We also investigated whether the structural
requirements toward degradation of Mus81 are the same as those
required for induction of G2 arrest by HIV-1 Vpr.
Results
To study the structure–function relationships in HIV-1 Vpr and
SIVagm.gri (henceforth, SIVagm) Vpr, a set of 4 chimeras and
2 truncations were constructed as shown in Fig. 1A. The exchange
points for the chimeras were designed based on the published
nuclear magnetic resonance (NMR) structure of HIV-1 Vpr and the
high degree of amino acid homology with SIVagm Vpr (Fig. 1B).
Determinants required for induction of G2 arrest
It was previously suggested that the C-terminal unstructured
region of HIV-1 Vpr was required to interact with a putative G2
arrest-related cellular factor (DeHart et al., 2007; Di Marzio et al.,
1995; Le Rouzic et al., 2007). In support of the previous notion, the
point mutant Vpr(R80A), although capable of interacting with
DCAF1, was unable to induce G2 arrest, and behaved as a
dominant-negative protein by competing with wild-type Vpr for
DCAF1 binding (DeHart et al., 2007).
We ﬁrst constructed two truncations in HIV-1 Vpr (Vpr1–80
and Vpr1–84; Fig. 1A) encoded by lentiviral vectors (Verrier et al.,
2011). HeLa cells were then transduced with VSV-G-pseudotyped
lentivirus vectors (Supplemental Fig. 1) encoding HIV-1 Vpr, HIV-1
Vpr (R80A) or each of the indicated truncations. As shown in
Fig. 2A and B, HIV-1 Vpr, but not HIV-1 Vpr (R80A), HIV-1 Vpr
(1–80), or HIV-1 Vpr (1–84) induced cell cycle arrest. The percen-
tages of cells transduced with the corresponding lentivirus vectors
are shown in Supplemental Fig. 2A.
While HIV-1 Vpr is able to induce cell cycle arrest in human
and non-human primate cells, SIVagm Vpr arrests AGM, but not
human cells (Planelles et al., 1996). We asked whether transposi-
tion of the C-terminal domain (HIV-1 Vpr residues 78–96) onto
SIVagm Vpr (Ch1) would confer upon SIVagm Vpr a de novo ability
to induce G2 arrest in human cells. As shown in Fig. 2C and D, Ch1
was able to induce G2 arrest in human cells. Therefore, the
inability of SIVagm Vpr to function in human cells can be over-
come by a determinant within the C-terminal domain of HIV-
1 Vpr.
Using the inactive truncation HIV-1 Vpr(1–80) as the recipient,
we asked whether grafting the C-terminus of SIVagm Vpr (Ch2)
would enable induction of G2 arrest in human cells. HeLa cells
transduced with the Ch2 also underwent cell cycle arrest (Fig. 2C
and D). The C-terminal domain of SIVagm Vpr is intrinsically
capable of recruiting the target leading to G2 arrest in human cells
when in the context of HIV-1 Vpr. One possible explanation for the
previous observation is that, while DCAF1 is highly conserved
across primate lentiviruses (Berger et al., 2014), the target protein
may be variable. In addition, these observations suggest that the
interaction of Vpr with the target may be dependent, in part, on
determinants that lie upstream of the C-terminal domain of Vpr.
In contrast with the above ﬁndings, transposition of the N-
terminal unstructured region of HIV-1 Vpr to SIVagm Vpr (Ch3)
did not confer upon this chimera the ability to induce G2 arrest in
human cells (Fig. 2C and D). The reciprocal exchange (Ch4), which
contained most of HIV-1 Vpr with the N-terminus of SIVagm Vpr,
was still capable of inducing arrest in human cells (Fig. 2C and D).
The above results indicate that the N-terminal unstructured region
of HIV-1 Vpr is not required to induce cell cycle arrest.
In an effort to test whether the chimeras maintained the
capacity to fold correctly, we veriﬁed their abilities to interact with
DCAF1. HIV-1 Vpr, SIVagm Vpr and chimeras Ch1 to Ch4 were able
to Co-IP with DCAF1 (Fig. 3, lanes 1 and 4). In contrast, the mutant
HIV-1 Vpr (Q65R), did not efﬁciently co-IP with DCAF1 (Fig. 3)
The amino terminal domain of SIVagm Vpr is required for degradation
of agmSAMHD1
SIVagm Vpr is bi-functional in AGM cells, where it can arrest
cells in G2 and induce degradation of agmSAMHD1. However,
SIVagm Vpr, when expressed in human cells, is unable to perform
either function (Lim et al., 2012). We wished to analyze which
domain(s) in SIVagm Vpr may be important for targeting agm-
SAMHD1 for degradation. To that end, we tested the chimeras
between SIVagm Vpr and HIV-1 Vpr. AgmSAMHD1 was degraded
by SIVmac Vpx and SIVagm Vpr (Fig. 4A, lanes 5 and 6,
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correspondingly) but not by HIV-1 Vpr (Fig. 4, lane 4) as previously
reported (Hrecka et al., 2011). Addition of epoxomycin to cells
transfected with SIVagm Vpr prevented the degradation of agm-
SAMHD1 (compare lanes 6 and 11), conﬁrming the involvement of
the UPS.
To examine the potential role of the C-terminal domain of
SIVagm Vpr in degradation of agmSAMHD1, we tested Ch1. As
shown in Fig. 4A, lane 7, Ch1 remained capable of inducing
degradation of agmSAMHD1. Therefore, the C-terminal domain
of SIVagm Vpr is dispensable for the degradation of SAMHD1. The
reciprocal chimera (Ch2) in which the C-terminus of SIVagm Vpr
was transferred onto HIV-1 Vpr (lane 8) failed to degrade agm-
SAMHD1. These results suggest that the C-terminal unstructured
region of SIVagm Vpr is not sufﬁcient to confer upon HIV-1 Vpr the
ability to degrade agmSAMHD1.
The N-terminal domain of SIVmac Vpx was previously shown
to be required to overcome SAMHD1 restriction in myeloid cells
(Ahn et al., 2012; DeLucia et al., 2013). To conﬁrm this notion, we
tested Ch3. As shown in Fig. 4A, lane 9, Ch3 failed to induce
degradation of agmSAMHD1. We interpret these data to mean that
the loss of the native N-terminal domain of SIVagm Vpr in Ch3
ablated the ability to target agmSAMHD1 for degradation. Previous
ﬁndings for the related protein, SIVmac Vpx, demonstrated that its
amino-terminal domain is required to induce hSAMHD1 degrada-
tion (Ahn et al., 2012; DeLucia et al., 2013). Therefore, we
speculate, by analogy, that the amino-terminal domain of SIVagm
Vpr is also required for degradation of agmSAMHD1.
Ch4, which contains the N-terminus of SIVagm Vpr (residues
1–26) followed by HIV-1 Vpr (residues 17–96), also failed to
trigger degradation of agmSAMHD1 (Fig. 4A, lane 10). Therefore,
we conclude that the N-terminal domain of SIVagm Vpr, although
required (see above), is not sufﬁcient for this function. Recently, a
crystal structure of a complex of DCAF1/SIVsmVpx/smSAMHD1
demonstrated that residues between the 2nd and 3rd alpha
helices of SIVsm Vpx interact with smSAMHD1 (Schwefel et al.,
2014). Therefore, by analogy, it is possible that a second determi-
nant required for degradation of agmSAMHD1 might lie in the
homologous location of SIVagm Vpr. Schwefel et al. (2014)
identiﬁed two residues in SIVsm Vpx, Met62 and Ser63, which
establish a hydrophobic interaction and a hydrogen bond, respec-
tively, with Lys622 and Phe621 in SAMHD1. SIVagm Vpr does not
have signiﬁcant conservation in this area and, speciﬁcally, equiva-
lent residues to Met62 and Ser63 are not present in SIVagm Vpr.
Degradation of Mus81 is independent of Vpr's ability to induce G2
arrest
The SLX4 complex was recently proposed as a target for HIV-1
Vpr (Laguette et al., 2014). In the presence of HIV-1 Vpr the Mus81
protein, a constituent of the SLX4 complex, is ubiquitinated,
contributing to the activation of the complex and leading to G2
arrest (Laguette et al., 2014). We observed that HIV-1 Vpr induces
degradation of Mus81 as reported by Laguette et al. (2014),
although to a modest degree (Fig. 5A).
We then asked whether the degradation of Mus81 correlated
with the ability of known HIV-1 Vpr mutants and homologs to
induce G2 arrest. We conducted these experiments in the presence
or absence of the neddylation inhibitor that blocks CRULs,
MLN4924 (Soucy et al., 2009) or the proteasome inhibitor, Epox-
omicin (Meng et al., 1999). Surprisingly, HIV-1 Vpr (R80A) (Fig. 5B,
compare lanes 3 and 11) and HIV-1 Vpr (Q65R) (compare lane
3 and 15 and Supplemental Fig. 3), two mutants that are deﬁcient
Fig. 1. Construction of chimeras between HIV-1 Vpr and SIVagm.gri Vpr; (A) schematic representation of the chimeras between HIV-1 Vpr and SIVagm Vpr. HIV-1 Vpr is
comprised of three alpha helices, symbolized as barrels, ﬂanked by amino-and carboxy-terminal unstructured regions that are connected by short ﬂexible loops. R represents
HIV-1Vpr and AGM represents SIVagm.gri Vpr. The subscript numbers denote the amino acid residues. (B) Alignment between HIV-1Vpr and SIVagm.gri Vpr, illustrating the
amino acid conservation between these two strains. An asterisk indicates fully conserved residues; colon represents amino acid conservation with strongly similar
properties; period designates amino acid conservation with weakly similar properties. Highlighted residues mark alpha helices and yellow stars mark residues Q65 and R80.
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Fig. 2. G2 arrest determinants are found in the C-terminal domains of HIV-1 Vpr and SIVagm Vpr. (A) Cell cycle analysis of HeLa cells transduced with VSV-G-pseudotyped
lentiviral vectors for HIV-1 Vpr, HIV-1 Vpr (R80A), HIV-1 Vpr (1–80) or HIV-1 Vpr(1–84). 48 h post-transduction, DNA staining (propidium iodide) was used to quantify the
cell cycle by ﬂow cytometry. (B) Positive values are above the mean percent of cells in G2 from 3 negative control repeats plus 3 times the standard deviation (line marked
with an asterisk) corresponding to a 99.7% interval of conﬁdence. (C) Cell cycle analysis of HeLa cells transduced with VSV-G-pseudotyped lentiviral vectors for HIV-1 Vpr,
SIVagm Vpr and each of the chimeras. These experiments were performed at least three times.
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in G2 arrest induction, degraded Mus81 to a similar degree as did
wild-type HIV-1 Vpr. Degradation of Mus81 for the above experi-
ment was quantiﬁed by densitometry (Fig. 5C). Vpr (Q65R) is
deﬁcient in binding to DCAF1 and, therefore, to degrade Mus81 it
may utilize a different DCAF than that involved in induction of
G2 arrest. Vpr (R80A) is thought to be unable to bind the putative
G2 arrest-related target, but is still able to induce degradation of
Mus81 (Fig. 5B lane 11). Therefore, it appears that the molecular
determinants of Mus81 degradation induced by Vpr are different
from those required for induction of G2 arrest.
We then asked whether V5-Mus81 was degraded in the
presence of chimeras 1–4 and also in the presence of Vpx and
SIVagm Vpr. As depicted in Fig. 5D, SIVmac Vpx and SIVagm Vpr
did not induce degradation of Mus81 (lanes 5 and 6). Ch1, a
construct that induces G2 arrest, did not target Mus81 for
degradation (lane 7). Ch2, which also induced G2 arrest, was able
to induce degradation of Mus81 (lane 8). Therefore, as we showed
above with the Vpr point mutants Q65R and R80A, the ability to
induce G2 arrest does not correlate with degradation of Mus81
when using our chimeric constructs. Furthermore, Ch2 is able to
induce Mus81 degradation in the absence of HIV-1 Vpr's unstruc-
tured C-terminal domain, pointing at another important difference
between the requirements for G2 arrest and degradation of Mus81.
Transpositon of the N-terminus of HIV-1 Vpr into SIVagm Vpr
(Ch3) did not lead to Mus81 degradation (Fig. 5D, lane 9). Ch4,
which contains the N-terminus of SIVagm Vpr (residues 1–26)
followed by HIV-1 Vpr (residues 17–96) induced degradation of
Mus81 (Fig. 5D, lane 10). These results suggest that the N-terminal
unstructured region of HIV-1 Vpr is also not critical for Mus81
degradation.
Inhibition of the proteasome with Epoxomicin caused stabili-
zation of Mus81 in the presence of HIV-1 Vpr or HIV-1 Vpr
(R80A) (Fig. 5B, compare lanes 4 to 7 and 11 to 12, respectively)
or HIV-1 Vpr (Q65R) (Supplemental Fig. 3). Because Epoxomicin
targets the proteasome, degradation of ubiquitinated proteins is
inhibited (Meng et al., 1999). Blockade of Cullin activity by the
neddylation inhibitor MLN4924 (Soucy et al., 2009) also stabi-
lized Mus81 in the presence of HIV-1 Vpr, HIV-1 Vpr (R80A)
(Fig. 5B; compare lanes 4 to 8 and 11 to 13) and HIV-1 Vpr (Q65R)
(Supplemental Fig. 3). Interestingly, treatment with Epoxomicin
but not with MLN4924, led to the stabilization of Mus81 (Fig. 5B,
compare lane 3 with 5 and 6). This result suggests that Mus81 is
controlled naturally by the ubiquitin–proteasome system but
independently of a CRUL. The above data, taken together with
the observation that Vpr (Q65R) is active at inducing degradation
of Mus81, suggests that Vpr manipulates a CRUL not containing
Fig. 3. Chimeras Co-IP with endogenous DCAF1. HEK293FT cells were transfected with HIV-1 Vpr, HIV-1 Vpr (Q65R), SIVagm.gri Vpr or each of the chimeras. 48 h post-
transfection cells were lysed and subjected to immunoprecipitation using magnetic beads coated with anti-HA antibody.
Fig. 4. The N-terminal unstructured domain of SIVagm Vpr is required for agmSAMHD1 degradation. 293FT cells were co-transfected with HA-agmSAMHD1 and with
vectors encoding HA-HIV-1 Vpr, HA-SIVagm Vpr, HA-SIVmac Vpx or each of the chimeras. 48 h post-transfection cells were harvested and the level of ectopic agmSAMHD1
was analyzed by Western blot using anti-HA. Results are representative of three independent experiments.
A.B. DePaula-Silva et al. / Virology 477 (2015) 10–1714
DCAF1, for targeting Mus81. We also observed that SIVagm Vpr,
which causes G2 arrest in AGM cells, was unable to degrade
agmMus81 (Supplemental Fig. 4), supporting that also for
SIVagm Vpr, degradation of Mus81 is independent of the induc-
tion of G2 arrest.
Discussion
The main conclusions from this study are as follows: (i) C-
terminal unstructured region of HIV-1 Vpr contains a determinant
required for induction of G2 arrest; transfer of the C-terminus of
HIV-1 Vpr onto SIVagm Vpr is sufﬁcient to confer upon this
chimera a de novo ability to induce G2 arrest in human cells;
(ii) carboxy-terminal unstructured region of SIVagm Vpr is intrin-
sically capable of recruiting the G2 arrest-related target in human
cells when transferred onto HIV-1 Vpr, but not in its native
conﬁguration within SIVagm Vpr; (iii) amino-terminal domain of
SIVagm Vpr is required for agmSAMHD1 degradation, although it
is not sufﬁcient; (iv) targeting Mus81 for degradation and induc-
tion of G2 arrest are independent, separable functions of HIV-1
Vpr; and (v) degradation of Mus81 by HIV-1 Vpr is proteasome-
and cullin-dependent, although it is likely that DCAF1 is not
involved in this activity.
The amino-terminal domain of SIVagm.gri Vpr, like the homo-
logous regions in HIV-2 and SIVmac (Ahn et al., 2012; DeLucia
Fig. 5. Degradation of Mus81 by HIV-1 Vpr is independent of G2 arrest induction. (A) HEK293FT cells were co-transfected with HA-HIV-1 Vpr (from 1 μg to 0.05 μg) and
constant amount of V5-Mus81. 48 h after transfection cells were lysed and the level of Mus81 was analyzed by Western blot using anti-V5 antibody. (B) HEK293FT cells were
cotransfected with V5-Mus81 and HIV-1Vpr, or HIV-1 Vpr (R80A), or HIV-1 Vpr (Q65R). 18 h prior to cell harvesting, Epoxomicin or MLN4924 were added to cells. Levels of
exogenous Mus81 were measured byWestern blot using anti-V5 antibody. (C) Quantiﬁcation of Mus81 normalized to β-actin from panel (B). The line indicates the basal level
of Mus81 in the presence of empty vector. Protein level below this line represents degradation of Mus81. (D) HEK293FT cells were co-transfected with V5-Mus81 and HIV-1
Vpr or SIVagm Vpr or SIVmac Vpx or each of the chimeras. (E) Quantiﬁcation of Mus81 normalized to β-actin from panel (D).
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et al., 2013) was required for degradation of agmSAMHD1. The
crystallographic data for SIVsm Vpx (Schwefel et al., 2014) showed
that Glu residues 15 and 16 establish ionic interactions with Arg
residues 609 and 617, respectively, in SAMHD1. While residues Glu
15 and 16 are conserved in HIV-2, SIVmac, SIVsm and SIVrcm Vpx,
SIVagm Vpr only contains one Glu residue in the corresponding
region (Glu 16). Therefore, it is tempting to speculate that Glu 16
from SIVagm Vpr may interact with either Arg 609 or 617 in
SAMHD1.
Our observations suggest that the inability of SIVagm Vpr to
induce G2 arrest in human cells is not intrinsic to this protein,
because its C-terminal domain, when grafted onto HIV-1 Vpr,
generates a chimera that is active. Because SIVagm Vpr is able to
bind hDCAF1, the species-speciﬁcity of this protein likely can be
explained based on the different ability to interact with SLX4
complex in the different species. Recently, it has been reported
that interaction between HIV-1 Vpr or SIV Vpr and SLX4 correlates
with induction of G2 arrest (Berger et al., 2014). Since Mus81 is
targeted for ubiquitination by Vpr (Laguette et al., 2014) we
decided to focus on this protein to investigate whether the
requirements for induction of G2/M arrest and Mus81 degradation
were the same. We found that HIV-1 Vpr induced degradation of
Mus81 through the proteasome system, by manipulating CRUL,
since addition of Epoxomicin or MLN4924 relieved this effect.
Interestingly, HIV-1 Vpr(R80A) and HIV-1 Vpr (Q65R) degraded
Mus81 in our hands. Therefore, our ﬁndings, at ﬁrst sight, appear
to be at odds with those of Berger et al. (2014), who reported that
knockdown of SLX4 (of which Mus81 is an integral component)
abolished the cell cycle arrest by the lentiviral proteins (Berger
et al., 2014). One possible explanation that might reconcile our
ﬁndings with those of Berger et al. (2014) could be if the modest
degradation of Mus81 that we and Laguette et al. (2014) observe is
simply not essential for induction of G2 arrest. It would still remain
to be explained why Vpr (R80A) is competent for interaction with
the SLX4 complex (Berger et al., 2014; Laguette et al., 2014), but
incapable of inducing G2 arrest.
Materials and methods
Cell lines and transfections
HeLa cells and HEK293FT (Invitrogen) were cultured in Dulbecco's
Modiﬁed Eagle's Medium (DMEM; Invitrogen, Carlsbad, CA) supple-
mented with 10% of fetal bovine serum (FBS) and 2mM of L-glutamine
(Invitrogen). HEK293FT cells were transfected by Calcium Phosphate
method. HeLa cells were transfected using FuGENE HD (Promega)
according to manufacturer's instruction.
Plasmids
HA-HIV-1Vpr, HA-SIVagm.gri Vpr (from Grivet monkeys), HA-
SIVmac Vpx, and each of the chimeras were PCR ampliﬁed and
cloned into pFIN-EF1-GFP-2A-mCherry-HA-WPRE, a kind gift of
Dr. Susan Semple-Rowland (Verrier et al., 2011) in place of
mCherry-HA. The truncations HIV-1 Vpr (1–80) and HIV-1 Vpr
(1–84) were generated on HIV-1Vpr using QuickChange Lightning
(Agilent Technologies). Mammalian expressing vector encoding
HA-agmSAMHD1 was a kindly provided by Dr. Michael Emerman.
hMus81 cDNA was purchased from DNASU, PCR ampliﬁed, N-
terminus tagged with V5 epitope cloned into pFIN vector (without
mCherry) in place of GFP.
Immunopreciptation and western blot
Cells were washed in PBS and lysed in NETN buffer, in the
presence of phosphatase (PhosSTOP; Roche) and protease (Complete
EDTA free tablets; Roche, Indianapolis, IN) inhibitors. The concentra-
tion of proteins were determined by PierceTM BCA (Thermo Scien-
tiﬁc, Rockford, IL). Magnetic Beads (SIGMA-ALDRICH, St. Louis, MO)
were coated with anti-HA antibody (HA1.1, Covance) for 30 min (RT).
For immunoprecipitation, cell lysates were incubated with the beads
coated with anti-HA for 1 h at 4 1C. Beads were washed 3 times with
NETN buffer and proteins were eluted in Lamelli buffer and boiled for
10 min. Samples were subjected to SDS-PAGE on 4–12% acrylamide
gel Criteron™ TGX gel (Bio-Rad, Hercules, CA) and transferred to
PVDF membrane (EMD Millipore, Billerica, MA). For degradation
assay, cells were lysed using SET buffer (1% SDS, 50 mM Tris–HCl, pH
7.4, 1 mM EDTA) and boiled for 20 min. Samples were resolves by
SDS-PAGE as described above. V5 antibody (Sigma-Aldrich), β-actin
(Sigma-Aldrich), rabbit polyclonal DCAF1 antibody was kindly pro-
vided by Dr. Ling-Jun Zhao (Saint Louis University).
Cell cycle analysis
HeLa cells were treated with trypsin, washed with PBS and
stained with Propidium Iodide (PI) using Hypotonic PI buffer
(Sodium Citrate, Triton X-100, Propidium Iodide, RNAse). Samples
were analyzed by ﬂow cytometry for DNA content. FlowJo was
then used to analyze the cell cycle.
Lentiviral vectors
Lentiviral were produced in HEK293FT cells. Brieﬂy, transfer
plasmid (12.5 μg), packaging plasmid (12.5 μg) and envelope
(5 μg) plasmid were co-transfected in HEK293FT cells by calcium
phosphate. Supernatants were collected every 12 h until mono-
layer died. Lentiviruses were concentrated by ultracentrifugation
25,000 rpm for 2 h at 4 1C. Viruses were titrated in HeLa cells.
Drugs
Epoxomicin (Calbiochem) was solubilized in DMSO and used at
1 μM. MLN4924 (MedChem Express) was diluted in DMSO and
used at 1 μM.
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